Dr Keith Flaherty talks with ecancer at the 2013 European Cancer Congress in Amsterdam about a study that compared the progression free survival and overall survival in melanoma clinical trials with trametinib, ipilimumab and vemurafenib.

The relationship between PFS and OS was established by looking at the hazard ratio reported in each of the studies and a series of sensitivity analysis.